(Reuters) - The chief executive officer of Valeant Pharmaceuticals, which made a $47 billion unsolicited offer for competitor Allergan Inc. on Tuesday, said during an interview on CNBC that he was "disappointed" with Allergan's so-called poison pill.
ALLERGAN (AGN.NY)on Tuesday night said that its board of directors had adopted a one-year stockholder rights plan to give it more time to consider takeover proposals. The Valeant offer was made with Pershing Square Capital Management hedge fund, which built up a stake in the company.
"We are disappointed but on the other hand, I think this deal will get done," Valeant CEO Michael Pearson said on Wednesday.
(Reporting by Caroline Humer; Editing by Chizu Nomiyama)
Relacionados
- Valeant formaliza su OPA sobre Allergan, propietario de 'Botox'
- Valeant formaliza su OPA sobre Allergan, propietario de Botox
- Economía/Empresas.- Valeant formaliza su OPA sobre Allergan, propietario de Botox
- La farmacéutica Valeant ofrece 33.000 millones por Allergan, el fabricante de la popular toxina cosmética Botox
- La farmacéutica Valeant se alía con Bill Ackman para comprar Allergan, propietario de 'Botox'
